diacerein

4 items

August 9, 2018

Castle Creek Pharmaceuticals Receives FDA Fast Track Designation for Diacerein 1% Ointment for Treatment of Epidermolysis Bullosa Simplex
Biopharmaceutical company currently evaluating diacerein 1% ointment (CCP-020) [...]
May 16, 2018

Castle Creek Pharmaceuticals Receives FDA Rare Pediatric Disease Designation for Diacerein 1% Ointment for Epidermolysis Bullosa
PARSIPPANY, N.J., May 16, 2018 – Castle Creek [...]
January 4, 2018

Castle Creek Pharmaceuticals to Participate in 5th Annual Dermatology Summit
Biopharma company developing therapies for orphan dermatologic conditions [...]
October 27, 2017

Castle Creek Pharmaceuticals Receives Partners in Progress Award from debra of America
Company recognized for clinical research in epidermolysis [...]